AdvaMed To FDA: IRB Uncertainty, Trial Recruiting Hamper CoA Studies
This article was originally published in The Gray Sheet
Executive Summary
Institutional review board confusion over FDA condition-of-approval (CoA) study requirements is a barrier to completing such studies, according to AdvaMed